Aestas Pharma Inc.

Aestas Pharma dedicated to the development of novel first-in-class disease-modifying therapeutics for early-stage Alzheimer’s and Parkinson’s disease.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded July 2015
  • Employees 3
  • Incorporation Type C-corp
  • Website aestaspharma.com

Company Summary

Aestas Pharma is dedicated to the development of novel first-in-class disease-modifying therapeutic agents to enable the REVERSAL of severely debilitating Alzheimer's diseases (AD) and Parkinson's disease (PD). In marked contrast to competitor approaches, Aestas is focused on targeting the very earliest stages of AD and PD, when clinical signs are not yet pronounced, in advance of significant plaque formation or neuronal loss.

Team

  • Sudarshan Upadhya
    Co-founder & Chief Scientific Officer

    Dr. Upadhya is a neuroscientist with 22 years of experience in the research underlying neurodegenerative disorders. Dr. Upadhya ’s research expertise is on molecular mechanism underlying synaptic plasticity during long-term memory formation and AD&PD, and drug metabolism in the brain. Dr. Upadhya has published 18 peer-reviewed international research papers, 24 scientific abstracts. Dr. Upadhya is an adjunct faculty of Geriatric Medicine.

  • Zahed Subhan
    Co-founder & CEO

    Dr. Subhan has 30 years experience in guiding pre-clinical & clinical development studies and gaining regulatory approvals for CNS and cancer products, as well as executing major product launches with multinational pharma companies. Dr. Subhan has also secured seed and VC funding for early-stage biotech companies as Founder & CEO. As CBO, Dr. Subhan also contributed to the $100MM IPO of Gemini Genomics Inc and its subsequent sale for $220MM.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free